Clinical trials: COMBO Condition
Stimulant Use (Diagnosis), Hiv
Contingency Management in HIV Care for Both Stimulant Use & ART Adherence
Methamphetamine use and associated sequelae have been rising, and represent a major barrier to successful control of the HIV epidemic.
- Trial name
- CoMBo (NCT06564792)
- Testing
- Contingency management
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of California, San Francisco
Breast Cancer, Renal Cell Carcinoma
Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma
MARIO-3 is a Phase 2 multi-arm combination cohort study designed to evaluate IPI-549, Infinity Pharmaceutical's first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells…
- Trial name
- MARIO-3 (NCT03961698)
- Testing
- IPI-549 (eganelisib), Atezolizumab, nab-paclitaxel
- Where
- 24 sites in United States
- Volunteers
- 91 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
HIV Infections
Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) in Combo Tablet for Patients Receiving Atripla With Viral Suppression in Taiwan
Prospective, Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) Plus Tenofovir Disoproxil Fumarate (TDF) and Lamivudine in a Fixed-Dose Combination Tablet (Combo) for Patients Receiving Co-Formulated TDF…
- Trial name
- NCT03595709
- Testing
- 3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg)
- Where
- 2 sites in Taiwan
- Volunteers
- 50 people
- Sponsor
- Yu-Jay Corp.
Thyroid Cancer
Focus on Values to Stimulate Shared Decisions
Most patients with non-medullary thyroid carcinoma (TC) achieve remission after primary treatment. Nonetheless, 30% develop recurrent disease and/or distant metastases resulting in worse survival.
- Trial name
- NCT03905369
- Testing
- Decision aid and SDM booster, Deliberation training
- Where
- 11 sites in Netherlands
- Volunteers
- 128 people
- Sponsor
- Radboud University Medical Center
Metastatic Melanoma, Brain Metastases
Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
1.1. Primary Objectives 1. To determine if nab-paclitaxel and temozolomide can be combined with full dose of bevacizumab for the therapy of patients with newly diagnosed brain metastases of metastatic malignant melanoma.
- Trial name
- NCT02065466
- Testing
- nab-paclitaxel, Temozolomide, Bevacizumab
- Where
- 2 sites in United States
- Sponsor
- University of Arizona
Hypercholesterolemia
A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)
This is a multicenter study to evaluate the safety and efficacy of ezetimibe/simvastatin versus rosuvastatin in participants with high cholesterol.
- Trial name
- NCT00479713
- Testing
- ezetimibe (+) simvastatin, Comparator : rosuvastatin calcium
- Volunteers
- 618 people
- Sponsor
- Organon and Co
COVID - 19, Influenza A
Evaluation of COVID-19 and Flu A/B 3 in 1 Combo Rapid Test
This observational study aims to evaluate the diagnostic performance of an investigational Influenza A/B and COVID-19 test in patients presenting with signs and symptoms of respiratory infection.
- Conditions
- COVID - 19, Influenza A, Influenza B
- Trial name
- NCT07190131
- Testing
- Investigational Flu A/B And Covid-19 Diagnostic Test
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 588 people
- Sponsor
- iHealth Labs inc
Diabetes Mellitus
Use of CoG by Patients With Diabetes Mellitus
The CNOGA Combo Glucometer (CoG) employs an invasive glucose meter using blood glucose teststrips and requiering a capillary blood sample obtained from a fingerstick and in addition, a non-invasive optical component for…
- Trial name
- NCT03840161
- Testing
- non-invasive tissue glucose prediction
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Sciema UG
Pulmonary Infection, Pulmonary Nodule
COMBO Endoscopy Oropharyngeal Airway in Sedated Fiberoptic Bronchoscopy for Patients: A Simon Two-Stage Trial
Hypoxia represents the prevailing adverse occurrence during the sedation of patients undergoing fiberoptic bronchoscopy with propofol.
- Conditions
- Pulmonary Infection, Pulmonary Nodule, Endotracheal Tumour, Bronchiectasis
- Trial name
- NCT07063290
- Testing
- the COMBO Endoscopy Oropharyngeal Airway
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Zhejiang University
Glaucoma, Ocular Hypertension
Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)
This study is comparing 2 medications for glaucoma and how effective they are at controlling glaucoma over the course of an entire day.
- Trial name
- NCT00108017
- Testing
- MK0507A, dorzolamide hydrochloride (+) timolol maleate, Comparator: timolol maleate, Duration of Treatment: Part 1) 6 wk timolol maleate run in
- Volunteers
- 330 people
- Sponsor
- Merck Sharp & Dohme LLC
Open Angle Glaucoma, Ocular Hypertension
Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT
This clinical trial, led by Dr. Enitan A. Sogbesan at the Hamilton Regional Eye Clinic, St. Joseph's Healthcare Hamilton, aims to compare the efficacy and safety of non-steroidal anti-inflammatory drug (NSAID) ketorolac alone…
- Conditions
- Open Angle Glaucoma, Ocular Hypertension, Postoperative Inflammation
- Trial name
- CES-NSLT (NCT06498440)
- Testing
- Ketorolac 0.5% Eye Drops, Ketorolac 0.5% and Fluorometholone 0.1% Eye Drops
- Where
- Canada
- Volunteers
- 126 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Hypertension
Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension
The purpose of this trial is to evaluate the safety and efficacy of combination therapy of aliskiren/hydrochlorothiazide (HCTZ) 150/25 mg and 300/25 mg compared with HCTZ 25 mg in patients with hypertension who do not show…
- Trial name
- NCT00387517
- Testing
- Aliskiren/HCTZ
- Where
- 2 sites in United States, Germany
- Volunteers
- 726 people
- Sponsor
- Novartis
Coronary Disease
EGO-COMBO Angiographic Extension Study
Evaluation of Endothelial ProGenitor Cell Capture Sirolimus-Eluting Stent by Optical Coherence Tomography: the COMBO Stent angiographic extension Study (EGO-COMBO angiographic extension Study)
- Trial name
- NCT01756807
- Testing
- The COMBO Stent
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Prof. Stephen Lee
Hypertension
A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients
To evaluate the blood pressure lowering effect and safety of the triple combination aliskiren / valsartan / HCTZ (300/320/25 mg) in patients with essential hypertension not adequately responsive to HCTZ 25 mg
- Trial name
- NCT00219193
- Testing
- aliskiren
- Where
- 2 sites in United States, Germany
- Volunteers
- 641 people
- Sponsor
- Novartis
Breast Cancer
Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast
In order to improve the survival of metastatic breast patients, it is important to investigate the use of novel therapeutic agents combined with known active agents in the treatment of breast cancer.
- Trial name
- NCT00473005
- Testing
- Capecitabine, RAD001
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Stanford University
Endothelial Dysfunction, Coronary Microvascular Disease
Functional Assessment of the Infart-related Artery With Bioactive and Polymer-free Coronary Stents (The FUNCOMBO Trial)
A total of 50 patients with ST-elevation myocardial infarction (STEMI) undergoing primary-percutaneous coronary intervention (PPCI) will be randomized to two different coronary stents: BIOFREEDOM vs. COMBO stent.
- Conditions
- Endothelial Dysfunction, Coronary Microvascular Disease, Myocardial Infarction
- Trial name
- FUNCOMBO (NCT04202172)
- Testing
- Stent implantation in the infart-related artery in patients with ST elevation myocardial infarction
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Institut d'Investigació Biomèdica de Bellvitge
Mild Cognitive Impairment, Cognitive Impairment
SNIFF - Combo INI+EMPA Trial
The proposed pilot study will provide safety and efficacy preliminary data regarding singular and combined effects of two therapeutic approaches, intranasal insulin and treatment with the sodium-glucose cotransporter type 2…
- Conditions
- Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease
- Trial name
- NCT05081219
- Testing
- Insulin (Humulin® R U-100), Empagliflozin 10 MG, Aptar Pharma CPS Intranasal Delivery Device
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Diabetes, Diabetes Mellitus, Type 1
A Trial to Assess the Efficacy and Safety of BioChaperone Combo and Humalog Mix 25 in Subjects With Type 1 Diabetes
BioChaperone Combo is a liquid formulation containing both Insulin Glargine and Insulin Lispro. The aim of this trial is to assess the efficacy and safety of BioChaperone® Combo in subjects with type 1 diabetes under a dose of…
- Trial name
- NCT01981031
- Testing
- BioChaperone® Combo, Humalog® Mix25
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Adocia
Coronary Artery Disease
Prospective Registry to Asses the Long-term Safety and Performance of the Combo Stent
Patients with stenosis in one or more coronary artery are often treated with a percutaneous coronary intervention (PCI). As part of the PCI treatment a stent is often placed to keep the vessel open over time.
- Trial name
- REMEDEE Reg (NCT01874002)
- Testing
- Combo stent
- Where
- 9 sites in Latvia, Luxembourg and 3 more
- Volunteers
- 1,000 people
- Sponsor
- Robbert J de Winter
Metastatic Cancer
An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced " Cold " Solid Tumors
This is an open-label study to evaluate the safety and the anti-tumor activity of the combination of nivolumab and celecoxib. The total numbers of participants to be enrolled will be up to 68 participants, depending on the…
- Trial name
- NICE-COMBO (NCT03864575)
- Testing
- Celecoxib 400 mg
- Where
- Belgium
- Volunteers
- 68 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain